Theravance Biopharma, Inc. (NASDAQ:TBPH) Holdings Boosted by PDT Partners LLC

PDT Partners LLC grew its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 31.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 87,177 shares of the biopharmaceutical company’s stock after purchasing an additional 20,738 shares during the period. PDT Partners LLC owned approximately 0.18% of Theravance Biopharma worth $703,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Quantbot Technologies LP purchased a new stake in Theravance Biopharma in the 3rd quarter worth approximately $60,000. China Universal Asset Management Co. Ltd. boosted its position in Theravance Biopharma by 64.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 3,696 shares during the last quarter. Ballentine Partners LLC purchased a new position in Theravance Biopharma in the third quarter valued at about $104,000. Hsbc Holdings PLC purchased a new stake in shares of Theravance Biopharma during the 2nd quarter worth about $108,000. Finally, XTX Topco Ltd purchased a new stake in shares of Theravance Biopharma during the 2nd quarter worth about $129,000. Institutional investors and hedge funds own 99.10% of the company’s stock.

Insider Transactions at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the transaction, the senior vice president now directly owns 322,743 shares of the company’s stock, valued at approximately $2,904,687. This trade represents a 1.22 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 6.90% of the stock is owned by insiders.

Theravance Biopharma Price Performance

TBPH stock opened at $9.44 on Tuesday. The company has a 50-day moving average of $8.72 and a two-hundred day moving average of $8.70. The stock has a market capitalization of $464.16 million, a price-to-earnings ratio of -9.35 and a beta of 0.25. Theravance Biopharma, Inc. has a 52-week low of $7.44 and a 52-week high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The company had revenue of $16.87 million during the quarter, compared to the consensus estimate of $16.11 million. During the same period last year, the company earned ($0.17) earnings per share. Equities analysts expect that Theravance Biopharma, Inc. will post -1.06 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on TBPH shares. TD Cowen dropped their price objective on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Theravance Biopharma in a report on Monday, September 16th. Leerink Partners cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $15.00 to $10.00 in a report on Tuesday, August 6th. Leerink Partnrs lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 6th. Finally, StockNews.com downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $13.75.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.